ENMost patients first meet the word “carcinomatosis” in an operation report or CT description, not from their doctor, usually beside a line saying radical treatment is impossible. Yet over the last twenty years, treatment of peritoneal carcinomatosis in Germany has come to include surgery for some, and the question is not whether such surgery exists but who is selected and on what grounds.
This page explains what peritoneal carcinomatosis is, how its extent is measured in Germany, which treatment options exist and what decides between surgery, drug treatment and supportive care; see also cancer treatment in Germany.
What peritoneal carcinomatosis is
Peritoneal carcinomatosis is tumour spread over the peritoneum, the thin membrane lining the abdomen and covering the organs: cells break away from the primary tumour, settle on it and form multiple nodules. It most often comes from colorectal, stomach, ovarian, appendiceal and pancreatic cancer. Pseudomyxoma peritonei stands apart: a rare appendix-derived condition managed by its own rules.
It is a topic of its own, not simply “stage four”: ascites (fluid in the abdomen), bowel obstruction, pain and weight loss shape how patients feel more than nodule size does, which is why treatment is planned differently than for liver or lung metastases. The primary tumours are covered under stage 4 colorectal cancer and stage 4 ovarian cancer.
How the situation is assessed in Germany
It starts with a second reading of the images and histology brought from home in a German laboratory, then CT of the chest, abdomen and pelvis, MRI and PET-CT if needed, and tumour markers. The aim is to see not only whether nodules exist but where, and whether the small bowel and its mesentery, the fold carrying its vessels, are involved.
A diagnostic laparoscopy is often proposed because CT systematically underestimates small nodules. Only a camera inside the abdomen allows the peritoneal cancer index (PCI) to be counted: each abdominal region is scored by nodule size, and the total shows how far the tumour has spread. It directly decides whether surgery is discussed at all; the surgeon names the values that matter for the specific diagnosis.
A tumour board, not one surgeon, decides: the visceral surgeon, oncologist, pathologist, radiologist and, for an ovarian primary, gynaecological oncologist. It works from the current German medical society guideline for the primary tumour, such as the guideline on colorectal cancer.
The treatment options
Systemic drug treatment is the basis for almost everyone: chemotherapy and, where molecular findings fit, targeted drugs and immunotherapy. For some it remains the only sensible option, and that is not “giving up on treatment”; see chemotherapy in Germany.
Cytoreductive surgery with HIPEC removes all visible deposits, then washes the abdominal cavity with heated chemotherapy on the operating table. It is a large, hours-long operation with a long recovery, discussed only with limited spread and good general condition, and decided in a centre that does such operations regularly. Its key part is removing all nodules: for colorectal and ovarian cancer, German guidelines still reserve the HIPEC step for studies. See also hyperthermia in cancer treatment.
PIPAC delivers chemotherapy into the abdomen as a pressurised aerosol through laparoscopic ports (small openings), repeated in courses. It is not an alternative to surgery but a separate approach, used more often with extensive carcinomatosis; in Germany specialised centres use it, and for stomach cancer the guideline allows it only within studies. Separately, some measures improve how patients feel: ascites drainage, a stent or bypass for obstruction, pain control and nutritional support.
Who is selected for surgery and why selection matters
Selection rests on factors the board weighs together: the PCI and where the nodules sit; the primary tumour type, since colorectal, appendiceal and ovarian results differ from gastric; response to previous chemotherapy; metastases outside the abdomen; age and other illnesses; nutritional state.
An honest conversation with the patient covers the risk of complications and recovery time, not only hope. If the board declines surgery, that does not mean there is no treatment; its goal changes to holding the disease back and easing symptoms.
Where this is done in Germany
Such operations are concentrated in visceral cancer surgery centres at university hospitals and large cancer hospitals. AlenMed’s partners include the Nordwest Hospital in Frankfurt, whose clinic for general, visceral and tumour surgery, headed by Prof. Thilo Welsch, lists treatment of peritoneal carcinomatosis including HIPEC. Another is the Red Cross Hospital in Munich: Prof. Wolfgang Thasler heads its department of general, visceral, thoracic and minimally invasive surgery, which runs colorectal and pancreatic cancer centres. Where a hospital’s page lists no HIPEC or PIPAC programme, only the department’s written answer confirms one.
Before travelling, ask the department how often it does such operations, who will operate, how long the stay lasts and what happens if laparoscopy shows that surgery is not possible.
Frequently asked questions
Can peritoneal carcinomatosis be treated?
Yes, there is almost always treatment, but its goal differs. With limited spread the board may discuss surgery plus drug treatment; for others systemic therapy remains the basis, and with severe symptoms relief comes first. The decision follows a document review, often a diagnostic laparoscopy too.
Can I travel to Germany directly for the operation?
Usually not: the German department reviews the documents first. Doctors study the images, histology and previous operation report, often propose repeat tests and a diagnostic laparoscopy, and only then does the tumour board decide whether surgery fits. The first trip is often for assessment.
How much does treatment of peritoneal carcinomatosis cost in Germany?
There is no single price: it depends on what the tumour board proposes. A document review with diagnostic laparoscopy, a course of drug treatment and cytoreductive surgery with a long stay are very different bills. The only reliable guide is the department’s written estimate; without it, any figure would be unverified.
How AlenMed arranges treatment
AlenMed sends a German department the discharge letters, previous operation report, histology blocks and slides, CT and MRI files and chemotherapy list. The doctor answers whether a diagnostic laparoscopy makes sense, which tests need repeating and how long the stay will be; then come a written estimate, a visa invitation and an interpreter at the tumour board and the report discussion.
Allow for a long trip if a major operation is likely, a companion, enough usual medication, translation of the final documents for your oncologist at home and an agreed plan in case surgery is declined.
This material is for information and is not an offer; a doctor decides the treatment plan in person.
News on this topic
Charité treats first beta-thalassemia patient with CRISPR
At Berlin Charité, a 19-year-old beta-thalassemia patient became the first in Germany to receive the newly approved CRISPR gene therapy Exagamglogene Autotemcel.
Real-World Breast Cancer Study Confirms High Five-Year Survival Rates in Germany
A landmark study of over 43,000 German patients reveals a five-year invasive disease-free survival rate of 82.9 percent in early hormone receptor-positive breast cancer.
FDA Approves Jülich Diagnostic Radiotracer FET for Brain Tumor Imaging
The FDA approves the diagnostic radiotracer FET (Pixclara®) for evaluating brain gliomas, highlighting decades of neuro-oncology research at Forschungszentrum Jülich.
